We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Ampligen

News List

AIM ImmunoTech reports no serious events from intranasal Covid-19 drug trial pharmaceutical-technology
April 09, 2021
AIM ImmunoTech has reported that no serious adverse events were observed in Cohort 1 of a Phase I AMP-COV-100 (CHDR2049) clinical study of its drug Ampligen as an intranasal therapy for Covid-19.
AIM ImmunoTech Begins Dosing for Intranasal Ampligen Clinical Study americanpharmaceuticalreview
March 15, 2021
AIM ImmunoTech has dosed the first healthy subjects in its Phase 1 clinical study on the safety of AIM’s drug Ampligen as a potential intranasal therapy. AIM’s ‘s goal is to develop Ampligen as a potential intranasal prophylaxis or early-stage ...
AIM ImmunoTech initiates dosing in intranasal Covid-19 drug study pharmaceutical-technology
March 10, 2021
AIM ImmunoTech has dosed the first healthy participants in a Phase I clinical study of its Ampligen drug as a potential intranasal prophylaxis or early-stage treatment for Covid-19 and other respiratory viral diseases.